AGIOS PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 32.92 USD | +1.42% |
|
-4.80% | +47.82% |
| May. 02 | Agios Pharmaceuticals Shares Rise After Reporting Smaller Q1 Loss | MT |
| May. 02 | Transcript : Agios Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 02, 2024 |
Presentation Operator MessageOperator (Operator)Good morning, and welcome to Agios' First Quar...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of alpha- and beta- thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
32.46
USD
Average target price
41.67
USD
Spread / Average Target
+28.36%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +47.82% | 1.84B | |
| +2.97% | 108B | |
| +10.21% | 105B | |
| +1.57% | 23.46B | |
| -12.77% | 21.72B | |
| -7.05% | 18.64B | |
| -37.64% | 17.45B | |
| -6.50% | 17.19B | |
| +6.00% | 13.99B | |
| +37.20% | 12.53B |
- Stock Market
- Equities
- AGIO Stock
- News Agios Pharmaceuticals, Inc.
- Transcript : Agios Pharmaceuticals, Inc., Q1 2023 Earnings Call, May 04, 2023